Collectively, our in vivo findings demonstrate that pharmacological inhibition of Ccr2 reduces macrophage infiltration and M2 marker (Arg1) expression in the kidney 7 days after AKI, as well as ameliorates renal fibrosis. Here, CCR2 is linked to renal fibrosis.